Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
NCT01867905 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 330
Last updated 2019-04-16
Summary
Sepsis is a significant cause health care expenditure and carries an extremely high rate of morbidity and mortality if not treated appropriately. From 1979 to 2000, sepsis resulted in over 10 million admissions to hospital in the United States with a mortality rate of 17.9 to 27.8 percent. In Canada, it is estimated that the incidence of sepsis from 2008-2009 was 103.3 per 100,000 per year.
Advances in the multifaceted management of sepsis in recent years have resulted in improved clinical outcomes. However, the cornerstone of sepsis management relies on the prompt administration of appropriate antibiotics. Current clinical practice suggests that antibiotic administration can be delayed up to 45 minutes in order to obtain blood cultures, whose results have a profound impact on the type and duration of antimicrobial therapy. Unfortunately, this recommendation is based on very little evidence and the investigators have found that potential life-saving treatment is often delayed in order to abide by it. Furthermore, recent data suggest that mortality could be increased by approximately 5% by delaying antibiotic administration for that time period.
The investigators therefore wish to organize a prospective, multi-centre trial in order to identify the effect of antibiotic administration on blood culture positivity in patients presenting with severe sepsis or septic shock. Other objectives will be to elucidate which patient factors, including age, co-morbid conditions and clinical presentation, as well as antibiotic choice will affect blood culture results.
This study will be conducted in the emergency departments at St. Paul's Hospital (SPH), Vancouver General Hospital (VGH), Lion's Gate Hospital (LGH), Surrey Memorial Hospital, Montreal General Hospital (MGH), Royal Victoria Hospital (RVH) and Maricopa Integrated Health System. Patients identified for the aforementioned conditions will be treated as per routine hospital protocol. If the patient is deemed eligible for the study, a second set of blood of blood cultures will subsequently be drawn ideally between 30 and 60 minutes after the administration of antibiotic therapy. Subject demographic data will be collected pertaining to age, comorbid immunocompromised conditions, vital signs, laboratory tests pertaining to end organ dysfunction, suspected source of sepsis, the type antibiotics administered and the timing of antimicrobial administration with respect to the second set of blood cultures taken.
Our hypothesis is that blood culture positivity in patients presenting with severe sepsis and septic shock will not be altered significantly by antibiotic therapy. If so, our study would strongly argue against delaying life-saving therapy and would thus greatly improve patient care in our local emergency rooms. If incorrect, our study would be the first to demonstrate the benefit of obtaining blood cultures before antibiotic therapy and would strengthen current recommendations.
Conditions
- Severe Sepsis
- Septic Shock
- Bacteremia
Sponsors & Collaborators
- collaborator OTHER
-
University of Arizona
collaborator OTHER -
University of British Columbia
lead OTHER
Principal Investigators
-
David Sweet, M.D. · University of British Columbia
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-03-01
- Primary Completion
- 2018-09-05
- Completion
- 2019-04-10
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Impact of COVID-19 on the Incidence, Characteristics, Management and Outcome of Sepsis
NCT04698382 ·Status: WITHDRAWN
-
Short-course Antimicrobial Therapy in Sepsis
NCT02899143 ·Status: UNKNOWN ·Phase: PHASE2
-
Prehospital Antibiotics Against Sepsis Trial
NCT01988428 ·Status: COMPLETED ·Phase: NA
-
Shock Indices Use for Early Mortality From Septic Shock
NCT05088109 ·Status: UNKNOWN
-
Study of Procalcitonin (PCT)-Guided Antibiotic Use in Severe Sepsis Patients Without Obvious Infection
NCT01025180 ·Status: TERMINATED ·Phase: PHASE4
-
Safety and Efficacy of Procalcitonin Guided Antibiotic Therapy in Adult Intensive Care Units (ICU's)
NCT01139489 ·Status: COMPLETED ·Phase: NA
-
Evaluation in the Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction With Conventional Blood Culture.
NCT01450358 ·Status: COMPLETED ·Phase: PHASE4
-
Septic Shock-induced Immunosuppression
NCT04067674 ·Status: RECRUITING
-
Therapeutic Plasma Exchange in Septic Shock: A Pilot Study
NCT05093075 ·Status: RECRUITING ·Phase: PHASE2
-
VTE Incidence in Severe Sepsis and Septic Shock
NCT02353910 ·Status: COMPLETED
-
Prolonged Intravenous Infusion of β-lactam Antibiotics in Early Septic Patients
NCT05024565 ·Status: UNKNOWN ·Phase: NA
-
Application of Biomarkers Change to Predict Outcome of Patient With Severe Sepsis
NCT02871895 ·Status: UNKNOWN
-
Procalcitonin Monitoring May Decrease Antibiotic Use in the Intensive Care Unit
NCT01085994 ·Status: UNKNOWN
-
Urinary Catheter Exchange on Admission of Septic Elderly With Permanent Catheter Before Initiation of Antibiotics
NCT00503282 ·Status: UNKNOWN
-
Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis
NCT06602245 ·Status: COMPLETED
-
Severe Sepsis/Septic Shock on Admission to the General Surgical ICU
NCT01363635 ·Status: RECRUITING
-
PCT Guided Antibiotics Use in Critically Ill Adult Patients in China
NCT06945510 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluation of Immunosuppression in Septic Shock: Biomarkers and Pharmacological Restoration (IMMUNOSEPSIS)
NCT02803346 ·Status: UNKNOWN
-
Safety and Efficacy of Extracorporeal Cytokine Hemoadsorption in Septic Shock in Critically Ill Cirrhotics
NCT03866083 ·Status: UNKNOWN ·Phase: NA
-
Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections
NCT00934011 ·Status: COMPLETED ·Phase: NA
-
Electronic Application of a Severe Sepsis Screening Tool and Management Bundle
NCT01724463 ·Status: UNKNOWN
-
Pilot Trial of External Warming in Septic Patients
NCT02706275 ·Status: COMPLETED ·Phase: NA
-
Integrated Clinical Decision Support for Empiric Antibiotic Selection in Sepsis
NCT06103500 ·Status: RECRUITING ·Phase: NA
-
GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
NCT00089986 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics and Pharmacodynamics of High Dose Ceftriaxone in Patients With Sepsis
NCT07245966 ·Status: COMPLETED